Efficacy and safety of ivabradine in Japanese patients with chronic heart failure ― J-SHIFT study ―

behalf of the J-SHIFT Study Investigators

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抜粋

Background: Increased heart rate (HR) is an independent risk factor for cardiovascular outcomes in chronic heart failure (HF). Ivabradine, an If inhibitor, improved outcomes in patients with HF and reduced ejection fraction (HFrEF) in the SHIFT study. We evaluated its efficacy and safety in Japanese HFrEF patients in a randomized, double-blind, placebo-controlled phase III study: the J-SHIFT study. The main objective was to confirm a hazard ratio of <1 in the primary composite endpoint of cardiovascular death or hospital admission for worsening HF. Methods and Results: Patients with NYHA functional class II-IV, left ventricular EF ≤35%, and resting HR ≥75beats/min in sinus rhythm under optimal medical therapy received ivabradine (n=127) or placebo (n=127). Mean reduction in resting HR was significantly greater in the ivabradine group (15.2 vs. 6.1beats/min, P<0.0001). However, symptomatic bradycardia did not occur. A total of 26 (20.5%) patients in the ivabradine group and 37 (29.1%) patients in the placebo group had the primary endpoint event (hazard ratio 0.67, 95% CI 0.40-1.11, P=0.1179) during median follow-up of 589 days. Mild phosphenes were reported in 8 (6.3%) patients in the ivabradine group and 4 (3.1%) patients in the placebo group (P=0.3760). Conclusions: The J-SHIFT study supported the efficacy and safety of ivabradine for Japanese HFrEF patients, in accord with the SHIFT study.

元の言語英語
ページ(範囲)2049-2060
ページ数12
ジャーナルCirculation Journal
83
発行部数10
DOI
出版物ステータス出版済み - 1 1 2019

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用